Articles
22.09.2025
ATMP Pricing in Practice: Success & Cautionary...

Advanced Therapy Medicinal Products (ATMPs) are leading in healthcare innovation, providing potentia...

Read more
Articles
17.09.2025
Why Gene Therapies Keep Hitting Price & Access...

The pricing benchmark has shifted faster than systems have adapted. In the UK, prices for one-time t...

Read more
Articles
03.09.2025
Proving LongTerm Value: Evidence Strategies Payers...

Proving the long-term value of pharmaceutical assets remains one of the biggest challenges for manuf...

Read more
Articles
26.02.2025
World EPA 2025: Evaluating the capabilities of AI ...

AUTHORS: Julia Tokarska, Ella Odams, Richard Sloggett, Graham Foxon OBJECTIVES  To evaluate if ...

Read more
Insider Insights
17.10.2024
A closer look at Spain’s new pharmaceutical acce...

Spain is set to implement a comprehensive reform to its law of guarantees and rational use of medici...

Read more
News
29.08.2024
ISPOR Europe 2024

We're delighted to announce our participation at ISPOR Europe 2024 in Barcelona this November. We'll...

Read more
Articles
28.08.2024
How to integrate Market Access strategy with evide...

Introduction What is the secret to a successful drug launch? One crucial factor is establishing a cr...

Read more
Publications
22.08.2024
ISPOR Europe 2024: Implications of Indication Expa...

We examine the impact of indication expansions on pricing and reimbursement strategies across EU4 an...

Read more
Publications
22.08.2024
ISPOR Europe 2024: Evaluating the Capabilities of ...

This study investigates the capabilities of AI tools including ChatGPT for conducting pricing and re...

Read more
07.08.2024
What does the right market access organisation str...

Effective pricing and market access (PMA) teams are vital for pharmaceutical companies to secure rei...

Read more

Stay in the know, subscribe to our newsletter

Be the first to receive exclusive content on the latest from the pharmaceutical and market access sector.